BioSpace News Archive

Genetown

Microbot Medical’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress

Microbot Medical Inc. (Nasdaq: MBOT) continues to strengthen its intellectual property (IP) portfolio, while advancing and securing its global commercialization strategy.

December 8, 2022
·
3 min read
Pharm Country

Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

Trevena, Inc. today announced that three abstracts related to the Company’s commercial and clinical pipeline were presented at medical meetings in December.

December 8, 2022
·
15 min read
FDA

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASHDesignation based on Akero’s Phase 2b HARMONY study

Akero Therapeutics, Inc. has received a Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of nonalcoholic steatohepatitis (NASH).

December 8, 2022
·
7 min read
Drug Development

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

IN8bio, Inc. today announced that it has received received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed glioblastoma (GBM).

December 8, 2022
·
6 min read
Lone Star Bio

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Instil Bio, Inc. today announced a reprioritization of its clinical programs to focus on development of its CoStAR-TIL product candidates.

December 8, 2022
·
4 min read
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney Expansion

XORTX Therapeutics Inc. is pleased to announce new proof of concept data demonstrating, in a second study, the effectiveness of xanthine oxidase inhibition (“XOI”) produced by the Company’s proprietary oral oxypurinol formulation, XORLO TM.

December 8, 2022
·
7 min read
Genetown

Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients

BIOXYTRAN, INC. announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients.

December 8, 2022
·
1 min read
Deals

Cabaletta Bio Announces $35 Million Offering

Cabaletta Bio, Inc. today announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock.

December 8, 2022
·
6 min read
Biotech Bay

Cepheid’s Multi-Target Test Design Enables Detection of Influenza Variants

Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests.

December 8, 2022
·
3 min read
Business

Evogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer

Evogene Ltd. announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.

December 8, 2022
·
1 min read